drugset / Trial / NCT05774704
Curcumin and Retinal Study
RandomizedParallel-groupTriple-blindOther
Summary
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
Timeline
- Start
- 2023-08-21
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Curcumin | Small molecule | 250 mg | — |
| Comparator | Curcumin | Small molecule | 500 mg | — |
Indications
No indication recorded.